

# Raynaud's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/R9ADC0AFE754EN.html>

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: R9ADC0AFE754EN

## Abstracts

The 7 major Raynaud's disease markets are expected to exhibit a CAGR of 7.68% during 2024-2034.

The Raynaud's disease market has been comprehensively analyzed in IMARC's new report titled "Raynaud's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Raynaud's disease is a medical condition which causes the blood vessels in the fingers, toes, nose, and ears to narrow down, thereby restricting the blood flow. This results in a lack of oxygen and nutrients reaching the damaged tissues, which can cause a range of symptoms. The affected areas may feel cold, numb, or tingling, and turn white or blue due to the lack of blood flow. As the blood flow returns, the impacted parts might become red and painful. In severe cases, repeated episodes of reduced blood flow can lead to tissue damage, ulcers, and even gangrene. The diagnosis of Raynaud's disease is typically based on the patient's medical history and physical examination. The physical exam focuses on the affected areas, looking for signs of decreased blood flow and tissue damage. Several additional procedures, such as blood tests or imaging studies, are suggested to rule out other conditions that can cause similar symptoms. In some cases, the healthcare professional may perform a cold stimulation test, in which the hands or feet are exposed to cold temperatures to see how they respond.

The increasing cases of abnormal blood vessel function, in which the blood vessels overreact and constrict more than necessary, leading to reduced blood flow and tissue damage, are primarily driving the Raynaud's disease market. In addition to this, the rising prevalence of several associated risk factors, such as the usage of certain medications like beta-blockers and chemotherapy drugs, genetic predisposition,

autoimmune disorders, etc., is also augmenting the market growth. Moreover, the widespread adoption of calcium channel blockers, including nifedipine, amlodipine, diltiazem, etc., to relax the blood vessels, which can enhance blood flow and reduce the symptoms of the ailment, is creating a positive outlook for the market. Besides this, the escalating utilization of sympathectomy, a surgical procedure that involves blocking the sympathetic nerves which regulate blood flow to the affected areas, for treating patients with severe, refractory Raynaud's disease, is also bolstering the market growth. Additionally, the emerging popularity of nailfold capillaroscopy, since it can detect abnormalities in the capillaries, such as enlarged or distorted vessels or loss of capillaries, and help to diagnose the ailment, is expected to drive the Raynaud's disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Raynaud's disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Raynaud's disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Raynaud's disease market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the Raynaud's disease market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Raynaud's disease market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Raynaud's disease marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the Raynaud's disease market performed so far and how will it perform in the

coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Raynaud's disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Raynaud's disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Raynaud's disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of Raynaud's disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Raynaud's disease by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of Raynaud's disease by type across the seven major markets?

How many patients are diagnosed (2018-2034) with Raynaud's disease across the seven major markets?

What is the size of the Raynaud's disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Raynaud's disease?

What will be the growth rate of patients across the seven major markets?

### Raynaud's Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Raynaud's disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Raynaud's disease market?

What are the key regulatory events related to the Raynaud's disease market?

What is the structure of clinical trial landscape by status related to the Raynaud's disease market?

What is the structure of clinical trial landscape by phase related to the Raynaud's disease market?

What is the structure of clinical trial landscape by route of administration related to the Raynaud's disease market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 RAYNAUD'S DISEASE - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 RAYNAUD'S DISEASE - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 RAYNAUD'S DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Epidemiology by Type (?2018-2034?)
  - 7.2.6 Diagnosed Cases (?2018-2034?)
  - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Epidemiology by Type (?2018-2034?)
  - 7.3.6 Diagnosed Cases (?2018-2034?)
  - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Epidemiology by Type (?2018-2034?)
  - 7.4.6 Diagnosed Cases (?2018-2034?)
  - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Epidemiology by Type (?2018-2034?)
  - 7.5.6 Diagnosed Cases (?2018-2034?)
  - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Epidemiology by Type (?2018-2034?)
  - 7.6.6 Diagnosed Cases (?2018-2034?)

- 7.6.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (?2018-2034?)
  - 7.7.4 Epidemiology by Gender (?2018-2034?)
  - 7.7.5 Epidemiology by Type (?2018-2034?)
  - 7.7.6 Diagnosed Cases (?2018-2034?)
  - 7.7.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (?2018-2034?)
  - 7.8.4 Epidemiology by Gender (?2018-2034?)
  - 7.8.5 Epidemiology by Type (?2018-2034?)
  - 7.8.6 Diagnosed Cases (?2018-2034?)
  - 7.8.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (?2018-2034?)
  - 7.9.4 Epidemiology by Gender (?2018-2034?)
  - 7.9.5 Epidemiology by Type (?2018-2034?)
  - 7.9.6 Diagnosed Cases (?2018-2034?)
  - 7.9.7 Patient Pool/Treated Cases (?2018-2034?)

## **8 RAYNAUD'S DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 RAYNAUD'S DISEASE - UNMET NEEDS**

## **10 RAYNAUD'S DISEASE - KEY ENDPOINTS OF TREATMENT**

## **11 RAYNAUD'S DISEASE - MARKETED PRODUCTS**

- 11.1 List of Raynaud's Disease Marketed Drugs Across the Top 7 Markets



- 11.1.1 Drug Name – Company Name
  - 11.1.1.1 Drug Overview
  - 11.1.1.2 Mechanism of Action
  - 11.1.1.3 Regulatory Status
  - 11.1.1.4 Clinical Trial Results
  - 11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

## **12 RAYNAUD'S DISEASE - PIPELINE DRUGS**

### 12.1 List of Raynaud's Disease Pipeline Drugs Across the Top 7 Markets

- 12.1.1 C 21 - Vicore Pharma
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 Profervia - Aisa Pharma
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 Onabotulinum toxin A - AbbVie
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Alprostadil topical - Seelos Therapeutics
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. RAYNAUD'S DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND**

## PIPELINE DRUGS

### 14. RAYNAUD'S DISEASE – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### 15 RAYNAUD'S DISEASE - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Raynaud's Disease - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Raynaud's Disease - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Raynaud's Disease - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Raynaud's Disease - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Raynaud's Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Raynaud's Disease - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Raynaud's Disease - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Raynaud's Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Raynaud's Disease - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)

- 15.5.2 Raynaud's Disease - Market Size by Therapies
  - 15.5.2.1 Market Size by Therapies (2018-2023)
  - 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Raynaud's Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Raynaud's Disease - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Raynaud's Disease - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Raynaud's Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Raynaud's Disease - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Raynaud's Disease - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Raynaud's Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Raynaud's Disease - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Raynaud's Disease - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Raynaud's Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Raynaud's Disease - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Raynaud's Disease - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Raynaud's Disease - Access and Reimbursement Overview

## **16 RAYNAUD'S DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 RAYNAUD'S DISEASE MARKET - SWOT ANALYSIS**

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 RAYNAUD'S DISEASE MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Raynaud's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/R9ADC0AFE754EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R9ADC0AFE754EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

